Replies to post #951 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>From Cox's early comments in the CC, it sounds like the alpha-1 anti-trypsin program is going to be rolled into this collaboration with LFB.<

Maybe.

I’m actually hoping that AAT remains separate from the LFB collaboration because it’s one of the plasma proteins that has greatest potential and I’m uncomfortable having too much of GTC’s future tied up with one partner.

[DewDiligence]

>As an aside - it's pretty clear that Navdeep Jaikaria from Rodman & Renshaw doesn't understand/remember the terms of the LEO partnership agreement…<

That wasn’t Navdeep on the CC—it was Sean Woo subbing for Navdeep. Woo was also on the previous CC and it’s clear that he does not follow GTC closely.